• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Nausea And Vomiting - Pipeline Review, Q2 2011 - Product Image

Nausea And Vomiting - Pipeline Review, Q2 2011

  • Published: April 2011
  • 101 pages
  • Global Markets Direct

Nausea And Vomiting - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Nausea And Vomiting - Pipeline Review, Q2 2011', provides an overview of the Nausea And Vomiting therapeutic pipeline. This report provides information on the therapeutic development for Nausea And Vomiting, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nausea And Vomiting. 'Nausea And Vomiting - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Nausea And Vomiting.
- A review of the Nausea And Vomiting products under development by companies and universities/research READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Nausea And Vomiting Overview
Therapeutics Development
An Overview of Pipeline Products for Nausea And Vomiting
Nausea And Vomiting Therapeutics under Development by Companies
Nausea And Vomiting Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Nausea And Vomiting Therapeutics - Products under Development by Companies
Nausea And Vomiting Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Nausea And Vomiting Therapeutics Development
BioDelivery Sciences International, Inc.
GlaxoSmithKline plc
Merck & Co., Inc.
A.P. Pharma, Inc.
Archimedes Pharma Limited
Aphios Corporation
Astellas Pharma Inc.
Eisai Co., Ltd.
Ono Pharmaceutical Co., Ltd.
Transcu Group Limited
ProStrakan Group plc
BioAlliance Pharma SA
Teikoku Pharma USA, Inc.
Simbec Research Ltd
Victory Pharma, Inc.
Ikano Therapeutics, Inc.
PepTcell Limited
Almac Discovery Ltd.
Acacia Pharma Ltd.
Nausea And Vomiting - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
EUR 1025 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ondansetron Spray - Drug Profile
Product Description
Mechanism of Action
R&D Progress
APF530 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PALO - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MGX006 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Granisetron + Dexamethasone + Prochlorperazine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aprepitant + Palonosetron + Dexamethasone for Nausea and Vomiting - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aprepitant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
APF530 + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ondansetron - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lerisetron - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK0869 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Emend - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fosaprepitant dimeglumine + Dexamethasone + Palonosetron - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Granisetron + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thiamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fosaprepitant dimeglumine + Ondansetron + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zindol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ramosetron - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Cyclophosphamide + Doxorubicin hydrochloride + Granisetron hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethason + Metoclopramide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone + Dronabinol + Palonosetron hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone + Gabapentin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone + Granisetron - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Emend + Kevatril + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metoclopramide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Emend - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Proemend - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gabapentin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ramosetron + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mephameson - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carbidopa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ondansetron - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metoclopramide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nausea And Vomiting Therapeutics – Drug Profile Updates
Nausea And Vomiting Therapeutics - Discontinued Products
Nausea And Vomiting - Featured News
Feb 16, 2011: Acacia Pharma Initiates Phase IIa Clinical Trial With APD421 For Nausea And Vomiting
Feb 16, 2011: Acacia Pharma Initiates Phase IIa Clinical Trial With APD421 For Nausea And Vomiting
Feb 09, 2011: A.P. Pharma Provides Update On APF530 Program
Sep 06, 2010: Acacia Pharma To Progress Two Projects For Nausea & Vomiting And Xerostomia Into Clinical Development
Jun 02, 2010: Merck Announced Results From Non-Inferiority Trial Of Fosaprepitant Dimeglumine And dexamethasone For Prevention Of Chemotherapy-Induced Nausea and Vomiting
Mar 25, 2010: SciClone Announces EU Approval For Ondansetron RapidFilm
Mar 23, 2010: BioDelivery Sciences Announces Positive Pre-IND Meeting On BEMA Granisetron Development Program
Mar 22, 2010: A.P. Pharma Receives FDA Complete Response Letter For APF530
Mar 15, 2010: Tranzyme's Clinical Results On Ulimorelin Selected For Oral Presentation At Digestive Disease Week 2010
Jan 12, 2010: BDSI To Discuss Planned BEMA Granisetron IND With The FDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Nausea And Vomiting, Q2 2011
Products under Development for Nausea And Vomiting – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Development by Companies, Q2 2011
BioDelivery Sciences International, Inc., 2011
GlaxoSmithKline plc, 2011
Merck & Co., Inc., 2011
A.P. Pharma, Inc., 2011
Archimedes Pharma Limited, 2011
Aphios Corporation, 2011
Astellas Pharma Inc., 2011
Eisai Co., Ltd., 2011
Ono Pharmaceutical Co., Ltd., 2011
Transcu Group Limited, 2011
ProStrakan Group plc, 2011
BioAlliance Pharma SA, 2011
Teikoku Pharma USA, Inc., 2011
Simbec Research Ltd, 2011
Victory Pharma, Inc., 2011
Ikano Therapeutics, Inc., 2011
PepTcell Limited, 2011
Almac Discovery Ltd., 2011
Acacia Pharma Ltd., 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Nausea And Vomiting Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Nausea And Vomiting, Q2 2011
Products under Development for Nausea And Vomiting – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Discovery and Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos